Rebecca Malott Email & Phone Number

Calgary, AB, CA

I am managing a diverse team of analysts devoted to the development and qualification/validation of analytical methods for release, stability, and characterization testing of new mRNA vaccine products for oncology and infectious diseases. I maintain relationships with international contract testing laboratories and manufacturing partners to support GMP.

• Led the development and optimization of analytical methods for testing new mRNA vaccine products and aa key contributor to developing analytical strategy and specification setting for new products.Key Contributions:
• Managed a team of up to 5 research associates, overseeing multiple development projects in parallel.
• Represented the analytical function on cross-functional asset development teams.
• Served as a subject matter expert for cell-based assay development. Established a cell-culture laboratory, including authoring procedure documents for cell-culture techniques, potency assays, and use of associated.

Calgary, Alberta, Canada

• Key Contributions:
• Led development activities in support of release, stability, and characterization assays for new products.
• Managed assay development and validation activities with partner testing laboratories.
• Key contributor to analytical strategy development and specification stetting for new products.

Calgary, Alberta, Canada

• The W21C Research and Innovation Centre is based in the University of Calgary’s O’Brien Institute for Public Health and the Calgary zone of Alberta Health Services. We conduct health systems research with the.
• Facilitating multiple industry partner projects in areas such as technology assessment, infection prevention and control, and examining the effectiveness and impact of health care innovations for patient care.
• Oversee the Healthcare Human Factors Simulation Laboratory.
• Responsible for hiring and performance management, and budget development and oversight.

Calgary, Canada Area

• Applied diverse research experience to support the Calgary innovation ecosystem through facilitating and accelerating translational health research. Key Contributions:
• Fostered interdisciplinary collaborations and built connections between University of Calgary innovators and local and international mentors, researchers, and resources.
• Served as program coordinator for the Early Cancer Detection Initiative, an innovation support program founded to advance cancer detection technology development.

Toronto, Canada Area

• Represented and managed the analytical function within global new vaccine project teams. Balanced a project portfolio of up to 3 new vaccine products simultaneously that ranged in stage from early development to.
• Established and led cross-functional sub-teams to develop the analytical testing strategies for new vaccine products.
• Coordinated all assay development, validation, and sample testing, supporting release of clinical trial material for clinical trials.
• Liaised with in-house laboratories and international contract research organizations, ensuring department met expected milestones, keeping the projects on target.

Toronto, Canada Area

• Applied scientific expertise to design, develop, and validate analytical test methods to support new vaccine products. Served as a subject matter expert for viral adventitious agents detection by compendial and.
• Led development of assays to accommodate complex test samples for adventitious agents testing. Designed and executed development experiments, improving standard operating procedures. Authored technical reports.
• Prepared and delivered presentations effectively on assay development strategies at global departmental meetings and at international vaccine industry meetings.
• Formed and headed a cross-functional team, optimizing and harmonizing a viral titration method across departments. Developed assay cooperatively, leading to a standard operating procedure successfully adopted by 4.
• Served as key member of a team, applying next generation molecular techniques to viral adventitious agents testing. Contributed work and expertise to 2 manuscripts published in peer-reviewed scientific journals.

Vancouver, Canada Area

• Spearheaded investigations into the role of membrane hopanoids in antimicrobial resistance of clinical isolates of Burkholderia multivorans: an opportunistic pulmonary pathogen that is highly resistant to most.
• Designed and executed experiments, delivering publishable results. Presented results at international meetings, showcasing work and inspiring discussion on the topic.
• Presented results at international meetings, showcasing work and inspiring discussion on the topic.
• Authored 2 manuscripts published in respected peer-reviewed scientific journals.
• Established a successful collaboration with Dr. Dianne K. Newman at Caltech, broadening studies to include a quantitative measure for membrane hopanoids in strains of B. multivorans.
• Acted as key contributor to grant submissions through project conceptualization and proposal writing.

Toronto, Canada Area

• Oversaw a multi-site, multidisciplinary study to characterize the Neisseria gonorrhoeae immunomodulatory metabolite that induces HIV-1 expression: elucidating the molecular mechanism for clinical and epidemiological.
• Managed collaborations with scientists from multiple disciplines, located at 2 different universities and 1 government laboratory.
• Authored a peer-reviewed manuscript published in a high-level scientific journal.
• Served as contributing inventor to a patent.
• Prepared and gave presentations on discoveries at local and international conferences.
• Awarded provincial-level fellowship.

Doctor Of Philosophy (Phd), Microbiology And Infectious Disease

Baccalaureate In Science (Bsc), Microbiology